KR840004783A - 생물학적으로 활성인 ws6049, 제조방법 및 제약학적 조성물 - Google Patents

생물학적으로 활성인 ws6049, 제조방법 및 제약학적 조성물 Download PDF

Info

Publication number
KR840004783A
KR840004783A KR1019830002276A KR830002276A KR840004783A KR 840004783 A KR840004783 A KR 840004783A KR 1019830002276 A KR1019830002276 A KR 1019830002276A KR 830002276 A KR830002276 A KR 830002276A KR 840004783 A KR840004783 A KR 840004783A
Authority
KR
South Korea
Prior art keywords
reaction
cdcl
nmr spectrum
color
brs
Prior art date
Application number
KR1019830002276A
Other languages
English (en)
Other versions
KR900004066B1 (ko
Inventor
스미오 기요도오 (외 5)
Original Assignee
후지사와 유우기찌로오
후지사와 야꾸힝 고오교오 가부시기가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 후지사와 유우기찌로오, 후지사와 야꾸힝 고오교오 가부시기가이샤 filed Critical 후지사와 유우기찌로오
Publication of KR840004783A publication Critical patent/KR840004783A/ko
Application granted granted Critical
Publication of KR900004066B1 publication Critical patent/KR900004066B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
    • C12P1/06—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using actinomycetales
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/03—Actinomadura
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/825—Actinomadura

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Steroid Compounds (AREA)
  • Light Receiving Elements (AREA)
  • Control Of Motors That Do Not Use Commutators (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

내용 없음

Description

생물학적으로 활성인 WS6049, 제조방법 및 제약학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 다음의 WS6049-A의 특성:
    1) 형태와 색: 무색분말
    2) 색반응: 양성: 드라겐로르프반응, 에르리히반응 및 세리움 설페이트반응 음성: 닌히드린반응
    3) 용해도: 용성: 메탄올, 아세톤 클로로포름, 약간용성: 디에틸에테르, 불용성: 헥산, 물
    4) 융점: 150℃(dec)
    8) 성분분석: C: 52.03%, H: 5.71%, N: 4.15%, S: 8.6%
    9) 박층크라마토그라피
    10) 분자량: FD매스: m/z 1333(M+Na), FABQMS: m/z 1311(M+1)
    겔루과 크로마토그라픈: 1100-1200
    11)13C NMR스펙트럼(CDCl3): δ(ppm):13.9,14.6,16.7,19.9,22.8,29.1,34.0,
    35.2,39.6,42.3,52.9,55.8,56.1,56.2,56.2,60.3,61.7,64.7,66.7,68.4,69.0,69.3,69.8,70.5,72.0,75.9,76.1,77.2,77.3,83.2,86.3,88.5,90.7,97.3,98.6,98.9,99.6,99.7,103.9,107.8,112.7,123.2,125.0,130.0,131.1,136.8,144.2,146.6,154.0,154.6,160.9,166.6,192.4.
    12)1H NMR 스펙트럼(CDCl3)
    δ(ppm): 8.57(1H,s), 87.48(1H,s), 6.6(1H,dd), 6.2(1H,d,J=1.6Hz), 6.18(1H,s), 5.93(1H,d,J=9.6Hz), 5.83(1H,dd,J=9.6,1.6Hz), 5.7(1H,d,J=2Hz), 5.5(1H,m), 5.48(1H,d,J=2.3Hz), 5.43(1H,brs), 4.97(1H,d), 4.7(2H,m), 4.56(1H,d,J=2.3Hz), 4.23(1H,s), 4.2-3.6(10-14H), 3.97(3H,s), 3.88(3H,s), 3.79(3H,s), 3.5(2H,m), 3.43(3H,s), 2.77(1H,s), 2.7(2H,m), 2.52(3H,s), 2.5(1H,m), 2.4-2.25(3H,m), 2.17(1H,s), 2.12(3H,s), 2.07(1H,m), 1.77(2H,s), 1.5(2H,m), 1.41(3H,d,J=6Hz), 1.35(3H,d,J=6Hz), 1.32(3H,d,J=6Hz), 1.2(4H,m).
    ii) 다음의 WS6049-B의 특성:
    1) 색 및 형태: 무색분말
    2) 색반응: 양성: 드라겐도르프반응, 에르디히반응 및 세리움설페이트반응, 음성: 닌히드린반응용
    3) 용해성: 양성: 메탄올, 아세톤 클로로포름, 약간용성: 디에틸에테르, 불용성: 헥산
    4) 융점: 145℃(dec)
    8) 성분분석: C: 51.58%, H: 5.75%, N: 4.27%, S: 9.80%
    9) 박층크로마토그라피
    10) 분자량: 겔투과 크로마토그라피 : 1100-1200
    11)13C NMR스펙트럼(CDCl3): δ(ppn): 13.8,16.7,17.6,19.8,22.7,29.1,33.
    9,34.1,35.2,39.5,52.8,55.8,56.1,56.3,61.0,61.5,64.6,66.7,68.4,69.0,69.3,69.8,70.4,71.9,75.9,76.2,76.7,77.2,77.3,77.6,83.2,86.6,88.3,90.7,97.3,98.6,99.0,99.6,99.7,103.9,109.8,112.7,123.2,124.9,129.8,131.0,136.8,144.2,146.3,154.0,154.6,160.9,166.6,192.4.
    12)1H NMR 스펙트럼(CDCl3): δ(ppm): 11.75(1H,s), 8.57(1H,s), 7.48(1H,s), 6.6(1H,dd), 6.24(1H,d,J=1.3Hz), 6.18(1H,brs), 5.93(1H,d,J=9.2Hz), 5.83(1H,dd,J=9Hz 및 1.3Hz), 5.70(1H,brd), 5.5(1H,m), 5.47(1H,d,J=2.3Hz), 5.42(1H,brs), 4.98(1H,d,J=9Hz), 4.7-4.6(2H,m), 4.56(1H,d,J=2.3Hz), 4.24(1H,s), 4.15-3.4(12,18H), 3.97(3H,J), 3.88(3H,s), 3.79(3H,s), 3.42(3H,s), 2.52(3H,s), 2.6-2.4(2H,m), 2.4-2.2(7-8H), 2.12(3H,s), 2.2-2.0(2H,m), 1.5-(2H,m), 1.4(3H,d,J=6Hz), 1.35(3H,d,J=6Hz), 1.33(3H,d,J=6Hz)을 지니는 WS6049-A와 WS6049-B에서 선택된 WS6049물질.
  2. 호기 조건의 영양배지액에서 WS6049를 생산할 수 있는 악티노마두라속에 속하는 종을 배양하고 WS6049-A 혹은 WS6049 B를 회수하는 단계로 구성되는 WS6049-A와 WS6049-B에서 선택된 WS6049 물질을 제조하는 방법.
  3. 제2항에 있어서 악티노마두라종이 악티노마두라 풀베라세우스 sp.nov.6049
    (ATCC39100)인 방법.
  4. 활성성분으로서 WS6049-A 및 WS6049-B에서 선택된 것과 무독성 제약학적 담체로 구성되는 제약학적 조성물.
  5. 악티노마두라 풀베라세우스 sp.nov.6049호(ATCC39100)순수 배양체.
  6. 제1항에 정의된 WS6049-A 물질.
  7. 제1항에서 정의된 WS6049-B 물질.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019830002276A 1982-05-24 1983-05-24 생물학적으로 활성인 ws 6049의 제조방법 KR900004066B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8215123 1982-05-24
GB8215123 1982-05-24

Publications (2)

Publication Number Publication Date
KR840004783A true KR840004783A (ko) 1984-10-24
KR900004066B1 KR900004066B1 (ko) 1990-06-11

Family

ID=10530585

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019830002276A KR900004066B1 (ko) 1982-05-24 1983-05-24 생물학적으로 활성인 ws 6049의 제조방법

Country Status (11)

Country Link
US (1) US4578271A (ko)
EP (1) EP0095154B1 (ko)
JP (2) JPS58212787A (ko)
KR (1) KR900004066B1 (ko)
AT (1) ATE24933T1 (ko)
AU (1) AU565322B2 (ko)
CA (1) CA1209935A (ko)
DE (1) DE3369158D1 (ko)
DK (1) DK232483A (ko)
ES (1) ES8501440A1 (ko)
SU (1) SU1308200A3 (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR78648B (ko) * 1982-07-26 1984-09-27 Bristol Myers Co
US4675187A (en) * 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
JPS606194A (ja) * 1983-06-23 1985-01-12 Meiji Seika Kaisha Ltd 新規抗生物質ｓｆ−２２８８及びその製造法
US4530835A (en) * 1983-07-08 1985-07-23 Warner-Lambert Company CL-1577 Antibiotic compounds and their production
US4868117A (en) * 1984-04-20 1989-09-19 Bristol-Myers Company BBM-1675, a new antitumor antibiotic complex
US4554162A (en) * 1984-05-04 1985-11-19 Warner-Lambert Company CL-1724 Antibiotic compounds, their production and use
GB8425685D0 (en) * 1984-10-11 1984-11-14 Lepetit Spa Antibiotic a 40926 complex
US5427941A (en) * 1985-08-08 1995-06-27 Schering Corporation Actinomadura brunnea var. antibiotica strains
IL79519A0 (en) * 1985-08-27 1986-10-31 Bristol Myers Co Bbm-1675c and d antitumor antibiotics
US4837206A (en) * 1987-04-29 1989-06-06 Bristol-Myers Company Esperamicin derivatives
US4952572A (en) * 1988-06-10 1990-08-28 Bristol-Myers Company BU-3420T antifungal antibiotic
US4916065A (en) * 1988-06-10 1990-04-10 Bristol-Myers Company BU-3420T Antitumor antibiotic
US5116845A (en) * 1990-05-04 1992-05-26 Bristol-Myers Company BU-3420T antitumor antibiotic
EP1470241A2 (en) * 2002-01-24 2004-10-27 Ecopia Biosciences Inc. Method, system and knowledge repository for identifying a secondary metabolite from a microorganism
US7119061B2 (en) 2002-11-18 2006-10-10 Vicuron Pharmaceuticals, Inc. Dalbavancin compositions for treatment of bacterial infections
US20060074014A1 (en) 2002-11-18 2006-04-06 Vicuron Pharmaceuticals Inc. Dalbavancin compositions for treatment of bacterial infections
HUE041133T2 (hu) 2002-11-18 2019-05-28 Vicuron Pharmaceuticals Llc Dalbavancin adagolási módszer bakteriális fertõzések kezelésére

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4195079A (en) * 1979-01-31 1980-03-25 Pfizer Inc. New polycyclic ether antibiotic
JPS56113791A (en) * 1980-02-15 1981-09-07 Kaken Pharmaceut Co Ltd Novel antibiotic and its preparation

Also Published As

Publication number Publication date
ES522637A0 (es) 1984-12-01
EP0095154A1 (en) 1983-11-30
JPH02257886A (ja) 1990-10-18
US4578271A (en) 1986-03-25
SU1308200A3 (ru) 1987-04-30
ES8501440A1 (es) 1984-12-01
JPH0415236B2 (ko) 1992-03-17
DK232483D0 (da) 1983-05-24
AU565322B2 (en) 1987-09-10
CA1209935A (en) 1986-08-19
JPH0216756B2 (ko) 1990-04-18
JPS58212787A (ja) 1983-12-10
DE3369158D1 (en) 1987-02-19
DK232483A (da) 1983-11-25
AU1488683A (en) 1983-12-01
EP0095154B1 (en) 1987-01-14
ATE24933T1 (de) 1987-01-15
KR900004066B1 (ko) 1990-06-11

Similar Documents

Publication Publication Date Title
KR840004783A (ko) 생물학적으로 활성인 ws6049, 제조방법 및 제약학적 조성물
EP0310321A3 (en) Immunomodulatory azaspiranes
KR910009729A (ko) 신규한 폴리펩티드 화합물과 그 제조방법
KR840002451A (ko) 3-히드록시-ml-236b 유도체의 제조방법
DE3479121D1 (en) Polysiloxane composition with improved surface wetting characteristics and biomedical devices made thereof
KR950701976A (ko) F0-1289 물질 및 그의 생산방법
FR2423540A1 (fr) Polysaccharide et son procede de preparation
EP1201763A3 (en) Production method of polyhydroxyalkanoate from substituted fatty acid ester as raw material
KR840006492A (ko) 플라티늄-디아민 착화물의 제조 방법
KR840003696A (ko) 2-케토-l-굴론산의 제조방법
KR840005023A (ko) 미생물을 함유한 헤어토닉 조성물의 제조방법
CA1081636A (en) Method for the cultivation of basidiomycetes belonging to the genus coriolus of polyporaceae
JPS5758884A (en) Preparation of glutathione peroxidase
KR870002253A (ko) 펩타이드 항생제
JPS5854796B2 (ja) ポリプレニルカルボン酸誘導体およびその製造法
KR890008325A (ko) 아미노디옥시 만니톨의 제법
JPS5528A (en) Preparation of coenzyme q9
KR890014457A (ko) 신규 아족시 화합물 및 그의 제조방법
JPS56154990A (en) Preparation of l-aminoacid oxidase
JPS5561795A (en) Preparation of insecticidal substance merejin
KR840000643A (ko) 구아노신의 제조법
ATE2339T1 (de) Verfahren zur herstellung von sphingomyelinase, sphingomyelinase und deren verwendung.
KR910003113A (ko) 항생물질 플러스박신
JPS5519070A (en) Preparation of benikoji pigment
JPS578788A (en) Preparation of coenzyme q

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19930319

Year of fee payment: 4

LAPS Lapse due to unpaid annual fee